Multiple myeloma (MM) patients are strongly vulnerable to infections, which remain a major cause of death. During infection, human immune cells sense the presence of invading pathogens through the Toll-like receptor family (TLR), which recognizes pathogen-associated molecular patterns (PAMP). We hypothesized that MM cells also could sense the presence of microorganisms, thus promoting myeloma disease progression. Here, we report that human myeloma cell lines (HMCL) and primary myeloma cells express a broad range of TLR, and are sensitive to the corresponding PAMP. Toll-like receptor 1, 7 and 9 are most frequently expressed by HMCL. The expression pattern of TLR does not correlate with the one of B cells, as TLR2 and 10 are lost while TLR3, 4 and 8 are acquired by some HMCL. Culture with TLR7-and TLR9-ligands saves HMCL from serum-deprivation or dexamethasone-induced apoptosis. Similarly, both ligands increase myeloma cell growth. These effects are mediated by an autocrine secretion of interleukin-6 (IL-6) since the neutralization of IL-6 blocks the growth and survival of HMCL. Thus, TLR expression and function are not restricted to the cells of the immune system and could be of advantage for cancer cells. In MM, recurrent infections could promote tumor growth and favor escape from standard therapies.
Introduction
Multiple myeloma (MM) is a fatal plasma cell malignancy mainly localized in the bone marrow. 1 Paradoxically, the clonal expansion of tumor cells is associated with the disappearance of normal plasma cells and with a marked depression in the production of normal immunoglobulin (Ig). This makes MM patients strongly vulnerable to bacterial, fungal and viral infections. Next to the general organ failure, recurrent infections remain a major cause of death in MM patients. Finally, MM is often newly diagnosed in the context of such infections. 2 However, their influence on the initiation and progression of the disease has not been fully investigated.
Microorganisms share highly conserved structures called pathogen-associated molecular patterns (PAMP). They are recognized by a family of receptors called the Toll-like receptor family (TLR), which act as sensors for the innate immune system. 3, 4 Toll-like receptor are type I transmembrane proteins bearing a cytoplasmic Toll/IL-1R homology domain. Ten TLR and nine agonists have been identified in humans. TLR1 and TLR2 are triggered by lipopeptides such as Pam3Cy5, 5 TLR3 by double-stranded RNA, 6 TLR4 by lipopolysaccharide (LPS), 7 TLR5 by flagellin, 8 TLR7 and 8 by single-stranded RNA (ssRNA), 9, 10 TLR9 by the unmethylated CpG DNA of bacteria and some viruses. 11 TLR are widely expressed in a variety of immune cells, such as monocytes/macrophages, neutrophils, eosinophils, dendritic cells (DC) and B cells. Upon PAMP recognition, immune cells are activated and cause a coordinated systemic defense to eliminate invading pathogens. [12] [13] [14] [15] Human B cells do express TLR1, 2, 7, 8, 9 and 10. 16, 17 They can proliferate and secrete IL-6 in response to LPS, CpG DNA or synthetic TLR7 ligands (Loxoribine or R848). Differentiation of B cells into plasma cells is observed after coactivation of the B-cell receptor (BCR) and/or plasmacytoid DC. 18, 19 Toll-like receptor expression is modulated during B-cell activation and early phases of plasma-cell differentiation. 17, 20 However, the fate and function of TLR at the end stage of this process has not been investigated.
Here, we report that human myeloma cells express a broad range of TLR. Furthermore, triggering TLR7 and 9 induces tumor cell growth and prevents chemotherapy-induced apoptosis. Finally, these effects are mediated by the induction of an autocrine loop of IL-6. Thus, myeloma cells could take advantage of infection to expand and escape the usual therapies.
Materials and methods

Human myeloma cell lines (HMCL) and primary myeloma cells
The XG1, XG6, XG7, BCN, MDN, SBN, NAN1, NAN2, NAN3, and HMCL have been established in our laboratory and are cultured in the presence of 3 ng/ml r-IL-6 (Novartis Pharmaceuticals, Basel, Switzerland). KMS11, KMS12 HMCL were kindly provided by Dr T Ohtsuki, Kawasaki Medical School, Japan. NCI-H929, and L363 HMCL were purchased from Deutsche Sammlung von Mikroorganismen and Zellkulturen (Braunschweig, Germany). RPMI-8226 and JJN3 were obtained from the American Type Culture Collection (Manassas, VA, USA). Human myeloma cell lines were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS), 2 mM glutamine and antibiotics. Bone marrow and peripheral blood from 12 patients with MM were collected for this study after informed consent. Mononuclear cells were obtained by centrifugation on Ficoll-hypaque medium and primary myeloma cells were then purified using CD138 microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany), as previously described. 21 RNA isolation, reverse transcriptase-polymerase chain reaction and quantitative real-time polymerase chain reaction Cells were lysed and total cellular RNA was extracted from HMCL or from freshly purified primary myeloma cells using 
Survival assay
Human myeloma cell lines were washed and starved as described above, then cultured at a concentration of 10 5 cells/ 200 ml in a 48-wells plate. For serum deprivation-induced apoptosis, cells were cultured in RPMI-1640 supplemented with 2% and compared to 10% FCS. To study the dexamethasone (Dex)-induced apoptosis, Dex was added at 10 À6 M. Toll-like receptor ligands were added at the beginning of the culture. After 3 days, cells were washed in phosphate buffered saline (PBS) and survival was determined with fluorescein isothiocyanate (FITC)-conjugated Annexin-V labeling (Beckman Coulter). Flow cytometry analysis was performed on a FACscan flow cytometer (Becton Dickinson, Mountain View, CA, USA).
TLR ligand sequences and concentrations
CpG DNA sequences (TLR9 ligand) were purchased from Sigma-Genosys. Small letters: phosphorothioate linkage; capital letters: phosphodiester linkage 3 0 of the base; bold: CpGdinucleotides; CpG 2006: 5 0 -tcgtcgttttgtcgttttgtcgtt-3 0 . CpG 2216: 5 0 -ggGGGACGATCGTCgggggg-3 0 ; Non-CpG sequence: 5 0 -ggGGGAGCATGCTGcggggG-3 0 . CpG and non-CpG sequences were used at the optimal concentration of 2 mg/ml.
The inhibitory oligonucleotide ODN TTAGGG and Loxoribine (TLR7 ligand) were purchased from Invivogen (San Diego, CA, USA) and used at 10 mg/ml and 800 mM respectively. Lipopolysaccharide from Escherichia coli (TLR4 ligand) was purchased from Sigma.
Neutralizing antibodies and cytokines
In some experiments, neutralizing antibodies to Interleukin-6 (IL-6) (B-E8) (Diaclone, France) and to IL-6R (R&D systems), at 10 and 2.5 mg/ml, respectively, were added at the beginning of the culture.
Analysis of cytokines
Interleukin-6 ELISA was used (Sanquin, Netherlands).
Results
Human myeloma cells express several TLR
We first analyzed the expression of TLR1 to 4 and 7 to 10 on 16 HMCL by semiquantitative RT-PCR. HT29, monocytes, and B cells were used as positive controls. TLR, expression was heterogeneous among HMCL ( Figure 1a ). Indeed, TLR1 was the most frequently expressed (15 þ /16, 93%), before TLR7 (11 þ / 16, 68%) and TLR9 (10 þ /16, 62%). On the contrary, TLR2 and TLR10 expressed by B cells were lost on most of the HMCL (6 þ / 16 (37%) and 5 þ /16 (31%), respectively). TLR3, 4 and 8 were not detected on B cells as previously reported, 16 but were surprisingly expressed by some HMCL (5 þ /16 (31%) for TLR3, 8 þ /16 (50%) for TLR4, and 2 þ /16 (12%) for TLR8). Each HMCL expressed at least one TLR (JJN3 and NAN2) and up to six (SBN, XG1, RPMI-8226) (mean: 3.871.6). The expression of TLR7 and TLR9 was confirmed and quantified by real-time PCR (Figure 1b) . B cells showed a very low to no expression of TLR7. RPMI-8226 and XG6 had a lower expression level of TLR9 as compared to B cells, but had a very low to no expression of TLR7. On the contrary, L363 and NAN3 had an expression profile opposite to that of B cells. Indeed, L363 and NAN3 expressed mainly TLR7, whereas they showed low to no expression of TLR9. We thereafter looked for the expression of TLR in primary myeloma cells isolated from the bone marrow of 12 patients, either at diagnosis or at relapse (11 with intramedullay myeloma, and one with plasma-cell leukemia). We first investigated the expression of TLR4, given it was aberrantly expressed by half of the HMCL. Surprisingly, only four out of 12 patient samples (33%) showed an expression of TLR4. We then looked at the expression of TLR7 and 9. According to the result obtained for HMCL, TLR7 and 9 were present in most of the patient samples (9 þ /12 (75%) and 7 þ /12 (58%), respectively). When taken together, these data indicate that human myeloma cells express a broad range of TLR.
TLR7 and TLR9 ligands promote human myeloma cell line survival
Given that TLR7 and TLR9 were the most frequently expressed among HMCL and primary myeloma cells, we investigated the effect of their ligands on cell growth and survival. We used Loxoribine, a synthetic immunostimulatory molecule as TLR7 ligand.
22 TLR9 ligand was a synthetic sequence of unmethylated CpG DNA, which strongly enhances human B-cell proliferation. 23 As mechanisms involved in the resistance to apoptosis play a major role in MM escape to therapies, we sought to determine Toll-like receptors and multiple myeloma G Jego et al the capacity of TLR ligands to promote the survival of HMCL. We first looked at the apoptosis induced by serum deprivation. To this end, we used NCI-H929 and L363 HMCL, which are IL-6 independent and both express TLR7 and TLR9. As shown in B cells  JJN3  NAN1  NAN2  NAN3  XG7  NCI-H929   SBN  MDN  BCN  XG1  XG6  RPMI8226   L363  KMS11  KMS12PE  KMS12BM   TLR1   TLR2   TLR3   TLR4   TLR10   Actine   TLR7   TLR8   TLR9   TLR4   TLR7   TLR9   Actine   B cells  Mono  MM1  MM2  MM3  MM4  MM5  MM6  MM7  MM8  MM9  MM10  MM11 Figure 2b ) and L363 from this induction of apoptosis (n ¼ 2 and 4, P ¼ 0.0027
respectively). We also tested the sensitivity of seven TLR7 pos HMCL to Dex. NAN1, NAN3, and L363 were sensitive to Dex and then used to evaluate the anti-apoptotic action of TLR7 ligand. Addition of Loxoribine totally protected NAN3 (n ¼ 6, P ¼ 0.0003) from Dex, as shown in Figure 2c . L363 was less protected, although still significantly so (data not shown) (n ¼ 5, Po0.0001). 
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Unmethylated CpG-DNA is a growth factor for human myeloma cells
Loxoribine did not enhance the proliferation of any of the six TLR7 pos HMCL, even at high concentration, as illustrated on Figure 3a by the L363 cell line. On the contrary, addition of increasing doses of CpG DNA 2006 enhanced the proliferation of XG6 (Figure 3b ) (mean of increase at 2 mg/ml: 3.1871.37, n ¼ 8). Increased proliferation was also observed for XG2 and RPMI-8226, but with a lower magnitude (data not shown). XG6 proliferation proved to be sequence dependent, as another DNA sequence (CpG-DNA 2216) known to act on DC did not show any effect (Figure 3c ). To test if this proliferation was mediated by TLR9, we cultured XG6 with a nonstimulatory sequence. No proliferation increase was observed (Figure 3c) . Furthermore, addition of an inhibitory DNA sequence (sequence from Invivogen), designed to compete with the binding of CpG DNA 2006 on its receptor, totally abrogated the induced proliferation, thus confirming the specificity (Figure 3d ). Finally, we looked at the ability of CpG DNA to support cell growth of XG6 in absence of cytokine (Figure 3e ). An increase of the number of XG6 cells was detectable at D4, and doubled at D8 in the presence of CpG DNA when compared to the culture in medium alone. These data indicate that CpG DNA is able to promote the growth of an IL-6-dependent HMCL through TLR9.
TLR7 and TLR9 ligands induce an autocrine secretion of IL-6
We next sought to identify factors mediating the proliferation and survival effect of TLR7 and TLR9 ligands on HMCL. IL-6 is a major myeloma growth factor and most of the HMCL used in this study are IL-6 sensitive. We used this to evaluate the role of IL-6 in our model. As shown in Figure 4a , neutralizing IL-6/IL6R abrogated the proliferation of XG6 induced by CpG DNA 2006 (n ¼ 3). Similarly, blocking IL-6 during the culture of NAN3 in the presence of Dex and Loxoribine reversed the antiapoptotic effect of Loxoribine. These data suggested that TLR7 and 9 ligands induce an autocrine secretion of IL-6 by HMCL. To test this hypothesis, we cultured the four HMCL, which previously showed significant response in the presence of CpG DNA or Loxoribine (XG6, NAN3, NCI-H929 and L363), and then looked for IL-6 in the supernatant after 24 h. As shown in Figure 4c /400 ml. At D4 and D8, cells were counted and diluted with fresh culture medium containing the initial CpG-DNA concentration. Counting was carried out in triplicate (n ¼ 2).
Toll-like receptors and multiple myeloma G Jego et al secretion of IL-6 was detected in the absence of stimulation. On the contrary, IL-6 was present in the supernatant of XG6 and NCI-H929 upon TLR9 triggering. Loxoribine also induced IL-6 secretion by NAN3. Of note, no IL-6 was detected when NCI-H929 was stimulated by Loxoribine, in spite of its expression of both TLR7 and TLR9. Finally, L363 did not produce any IL-6 on stimulation neither by CpG DNA nor by Loxoribine.
Discussion
Cells from the immune system sense invading microorganisms through TLR. We here show that MM cells also express TLR and are stimulated upon PAMP triggering. TLR7 and TLR9 are the TLR the most frequently expressed by HMCL. Thus, HMCL are triggered by CpG DNA or Loxoribine to proliferate or to be rescued from apoptosis. These effects are mediated by the induction of an autocrine secretion of IL-6 by the responsive HMCL.
In this study, we focused on TLR7 and 9, as they are expressed by a majority of HMCL as well as by primary myeloma cells. However, HMCL express several TLR showing a heterogeneous expression pattern that does not correlate with that of B cells. Toll-like receptor 1 and 2 form heterodimers in B cells, monocytes and DCs. 24 Biological response to their ligand (lipopeptide and Pam-3-cys) thus requires the presence of both TLR. In MM, we showed that, whereas TLR1 is expressed by almost all HMCL, TLR2 is weakly expressed on a minority of them. Human myeloma cell lines are therefore unlikely to be sensitive to lipopeptide and Pam-3-cys. Among cells of the immune system, TLR10 is strongly and exclusively expressed on B cells. 16 We here show that HMCL lack TLR10 expression. These observations suggest a loss of expression of both TLR2 and 10 during the normal and/or malignant plasma-cell differentia- Toll-like receptors and multiple myeloma G Jego et al tion. Given this lack of expression, the identification of TLR10 ligand would permit to target B cells exclusively, without affecting myeloma cells.
KMS12PE and KMS12BM are two HMCL derived from one single patient, from pleural effusion and bone marrow, respectively. They show different surface markers and responses to growth factors. 25 Here, we add TLR pattern of expression to this discrepancy. Indeed, TLR4 and 7 are more expressed in KMS12PE than in KMS12BM, and TLR9 is only detectable in KMS12BM. These differences may be related to the stage of the disease, as they have been isolated 2 months apart. The origin of both cell lines could also cause the differences, because of varying cytokine presence and cell-cell interaction between bone marrow and pleura environment. In support of this hypothesis, IFN-alpha has been shown to upregulate the expression of TLR7 in naïve B cells. 26 Normal plasma-cell differentiation occurs in the context of infection and is controlled by DC. 27 We have previously characterized reactive plasmacytosis (RP) as being major polyclonal expansions of plasmablasts and immature plasma cells in human blood. 28 Reactive plasmacytosis are frequently detected in diverse infectious contexts and reactive plasma cells are IL-6 dependent for their survival. Reasons for RP development are not fully understood. Given that myeloma cells express several TLR whose triggering enhance their expansion, it would be interesting to evaluate the expression of TLR on normal reactive plasma cells and their putative role in RP appearance.
Some strategies of cancer immunotherapy suggest to target DC through their exclusive set of TLR. Indeed, CpG DNA has proved to be a potent adjuvant for therapy in numerous murine models of tumors. [29] [30] [31] [32] Given the shared expression of TLR between DC and myeloma cells, we suggest such strategies to be used with caution for MM. In addition, TLR ligands may also favor myeloma cells growth through the activation of bonemarrow-resident DC. This caveat is also true for most B-cell malignancies, including B-cell chronic lymphocytic leukemia, B-cell small lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma and marginal zone B-cell lymphoma, as they express TLR9 and are activated by CpG DNA. 33 Several solid tumors (colon, melanoma, breast, prostate and lung cancer) have recently also been reported to express TLR. 34 Triggering of TLR4 by LPS induces the secretion of IL-6 and nitric oxide, subsequently inhibiting T-cell activation and contributing to immune evasion. Similarly, secretion of IL-6 by myeloma cells could also contribute to inhibit the antimyeloma immune response.
Multiple myeloma clonal expansion within the bone marrow strongly inhibits normal B-cell ontogeny, as well as polyclonal Ig production. Consequently, protection against infections is impaired. On the basis of our data, we emit the hypothesis that a vicious circle takes place, where myeloma cells could take advantage of infections. The increased sensitivity to infection could stimulate myeloma cell growth or survival by PAMP. Multiple myeloma patients would therefore face a risk of relapse or progression during the evolution of an infection, which would further drive the depression in B cell quantity and Ig production. In this regard, clinical investigation is necessary to determine whether infection results from tumor progression or, conversely, infection leads to progression and relapse. A search for a possible implication of infections in the transition from Monoclonal Gammapathy of Undetermined Significance to MM, as well as from a remission phase of MM to a relapse, would be of major interest.
In conclusion, our results suggest a novel role for PAMP through TLR, that is, growth and survival factors for tumor cells.
The broad range of TLR expressed by myeloma cells gives them the faculty to hijack various types of infections to their own benefit. Finally, our results stress the need for careful monitoring of infection events in MM patients.
